Rapid Malaria Test Evaluated In Different Locales
By LabMedica International staff writers Posted on 20 Jun 2013 |

Image: VIKIA Malaria rapid diagnostic test (Photo courtesy of IMAccess).
A recently introduced malaria rapid diagnostic test (RDT) has been evaluated in an area endemic for the disease in Africa and in a nonendemic setting in Europe.
The RDTs are a useful tool in endemic malaria countries, where light microscopy is not feasible and in nonendemic countries where they can be used as complementary tests to provide timely results in case of microscopy inexperience.
Scientists at the Hospices Civils de Lyon (France) working with colleagues in Mali, tested blood samples that were collected during a 12-months and six-months period in 2011 from patients suspected to have malaria in Lyon and Bamako, respectively. Samples of 877 patients from both sites were included in the study.
The samples were examined by light microscopy, the VIKIA Malaria Ag Pf/Pan RDT (IMAccess; Lyon, France) and in Bamako additionally with the CareStart RDT (AccessBio, Somerset, NJ, USA). All discordant results between microscopy and the two RDTs were resolved by a real time polymerase chain reaction (PCR) and test characteristics were recalculated according to the PCR-corrected results. Sensitivity, specificity, positive predictive value, and negative predictive value were used to evaluate test performance.
The VIKIA Malaria Ag Pf/Pan RDT is an immunochromatographic test in which monoclonal antibodies target the histidine-rich protein II (HRP-II) protein antigen specific to Plasmodium falciparum and the Pan Aldolase antigen, common to all the Plasmodium species. This RDT had sensitivity for Plasmodium falciparum of 98% in Lyon and 96% in Bamako, and its performance was similar to PCR-corrected microscopy. No significant difference in the detection of falciparum and non-falciparum malaria between the two RDTs was observed. The performance of the VIKIA RDT was not significantly different for P. falciparum and non-falciparum species compared to PCR-corrected microscopy method.
The authors concluded that the VIKIA Malaria Ag Pf/Pan showed a similar level of performance to comparative RDTs in endemic and in nonendemic settings. Community health workers were as efficient as medical students in managing malaria cases using both RDTs tested. This RDT, which has recently become commercially available, could be used to implement efficient malaria diagnosis in low-income endemic countries or complement PCR/microscopy diagnosis in nonendemic regions. The study was published on June 6, 2013, in the Malaria Journal.
Related Links:
Hospices Civils de Lyon
IMAccess
AccessBio
The RDTs are a useful tool in endemic malaria countries, where light microscopy is not feasible and in nonendemic countries where they can be used as complementary tests to provide timely results in case of microscopy inexperience.
Scientists at the Hospices Civils de Lyon (France) working with colleagues in Mali, tested blood samples that were collected during a 12-months and six-months period in 2011 from patients suspected to have malaria in Lyon and Bamako, respectively. Samples of 877 patients from both sites were included in the study.
The samples were examined by light microscopy, the VIKIA Malaria Ag Pf/Pan RDT (IMAccess; Lyon, France) and in Bamako additionally with the CareStart RDT (AccessBio, Somerset, NJ, USA). All discordant results between microscopy and the two RDTs were resolved by a real time polymerase chain reaction (PCR) and test characteristics were recalculated according to the PCR-corrected results. Sensitivity, specificity, positive predictive value, and negative predictive value were used to evaluate test performance.
The VIKIA Malaria Ag Pf/Pan RDT is an immunochromatographic test in which monoclonal antibodies target the histidine-rich protein II (HRP-II) protein antigen specific to Plasmodium falciparum and the Pan Aldolase antigen, common to all the Plasmodium species. This RDT had sensitivity for Plasmodium falciparum of 98% in Lyon and 96% in Bamako, and its performance was similar to PCR-corrected microscopy. No significant difference in the detection of falciparum and non-falciparum malaria between the two RDTs was observed. The performance of the VIKIA RDT was not significantly different for P. falciparum and non-falciparum species compared to PCR-corrected microscopy method.
The authors concluded that the VIKIA Malaria Ag Pf/Pan showed a similar level of performance to comparative RDTs in endemic and in nonendemic settings. Community health workers were as efficient as medical students in managing malaria cases using both RDTs tested. This RDT, which has recently become commercially available, could be used to implement efficient malaria diagnosis in low-income endemic countries or complement PCR/microscopy diagnosis in nonendemic regions. The study was published on June 6, 2013, in the Malaria Journal.
Related Links:
Hospices Civils de Lyon
IMAccess
AccessBio
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more